1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Shukra Pharmaceuticals Limited

Shukra Pharmaceuticals Limited

SHUKRAPHAR.BO
Shukra Pharmaceuticals LimitedIN flagBombay Stock Exchange
33.05
INR
+0.66
- -
14.47BMarket Cap

Total Valuation

Shukra Pharmaceuticals Limited carries a market capitalization of 14.47B, placing it among publicly traded companies globally. Its enterprise value stands at 14.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap14.47B
Enterprise Value14.04B

Share Statistics

Shukra Pharmaceuticals Limited currently has 437.88M shares outstanding.

Shares Outstanding437.88M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Shukra Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 63.72. The price-to-sales ratio is 24.77, and the price-to-book ratio stands at 32.09.

PE Ratio63.72
PS Ratio24.77
PB Ratio32.09
P/TBV Ratio15.64
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Shukra Pharmaceuticals Limited trades at an EV/EBITDA multiple of 55.52 and an EV/FCF ratio of 1,676.68. The EV/Sales ratio of 24.76 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 55.52 provides insight into valuation relative to core operating earnings.

EV / Sales24.76
EV / EBITDA55.52
EV / EBIT55.52
EV / FCF1,676.68

Financial Position

Shukra Pharmaceuticals Limited maintains a current ratio of 3.63, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.59, indicating elevated leverage, while an interest coverage ratio of 23.14 demonstrates strong ability to service its debt obligations.

Current Ratio3.63
Quick Ratio0.26
Debt / Equity5.59
Debt / EBITDA0.20
Interest Coverage23.14

Financial Efficiency

Shukra Pharmaceuticals Limited posts a return on equity of 43.30 and a return on invested capital of 23.94.

Return on Equity (ROE)43.30
Return on Assets (ROA)21.60
Return on Invested Capital (ROIC)23.94
Return on Capital Employed (ROCE)41.22
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.33

Taxes

Over the trailing twelve months, Shukra Pharmaceuticals Limited has paid 67.29M in income taxes, reflecting an effective tax rate of 23.38.

Income Tax67.29M
Effective Tax Rate23.38

Stock Price Statistics

Shukra Pharmaceuticals Limited's stock has gained approximately 80.79869% over the past 52 weeks. The 50-day moving average sits at 30.27, while the 200-day moving average is 38.44.

Beta (5Y)N/A
52-Week Price Change80.79869%
50-Day Moving Average30.27
200-Day Moving Average38.44
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Shukra Pharmaceuticals Limited generated 567.27M in revenue and converted that into 220.56M in net income, yielding earnings per share of 0.48. EBITDA reached 252.93M, while operating income came in at 252.93M.

Revenue567.27M
Gross Profit408.78M
Operating Income252.93M
Pretax Income287.84M
Net Income220.56M
EBITDA252.93M
EBIT252.93M
Earnings Per Share (EPS)0.48

Balance Sheet

Shukra Pharmaceuticals Limited holds 59.76M in cash and equivalents against 50.20M in total debt, resulting in a net debt position of -9.57M. Total book value stands at 437.88M, with working capital of 607.18M providing operational flexibility.

Cash & Cash Equivalents59.76M
Total Debt50.20M
Net Debt-9.57M
Equity (Book Value)437.88M
Book Value Per Share0.95
Working Capital607.18M

Margins

Shukra Pharmaceuticals Limited operates with a gross margin of 72.06, reflecting its pricing power and cost economics. The operating margin of 44.59 and net profit margin of 38.88 provide insight into operational efficiency.

Gross Margin72.06
Operating Margin44.59
Pretax Margin50.74
Profit Margin38.88
EBITDA Margin44.59

Stock Splits

Shukra Pharmaceuticals Limited's most recent stock split took place on March 21, 2025 with a 1:10 split ratio.

Last Split Date3/21/2025
Split Ratio1:10

Scores

Shukra Pharmaceuticals Limited posts an Altman Z-Score of 32.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score32.37